211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
348 articles with Daiichi Sankyo
2/23/2018The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.
Daiichi Sankyo Initiates Phase I Study of U3-1402 in Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Treatment with EGFR TKIs such as erlotinib, gefitinib, or afatinib is used as first-line therapy for metastatic EGFR-mutated NSCLC.
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients With HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Updated preliminary subgroup analysis results in 44 of 45 efficacy evaluable patients with HER2-expressing gastric cancer or gastroesophageal junction adenocarcinoma previously treated with trastuzumab and chemotherapy showed that DS-8201 demonstrated a confirmed overall response rate of 45.5 percent and a disease control rate of 81.8 percent.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
Daiichi Sankyo's Once-Daily, Oral SAVAYSA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
The Hokusai-VTE CANCER study met the primary objective of non-inferiority of edoxaban for the composite outcome of first recurrent VTE or ISTH-defined major bleeding during a 12-month study period.
Daiichi Sankyo Presents Phase I Data for EZH1/2 Dual Inhibitor DS-3201 in Patients With Non-Hodgkin Lymphomas at the 59th Annual Meeting of the ASH
Preliminary exploratory efficacy results from an ongoing phase 1 dose escalation study showed that an overall response rate of 58.8 percent was observed with single agent DS-3201 in 17 evaluable patients with NHLs, including B-cell and T-cell lymphomas, who were relapsed from or refractory to standard treatment or for whom no standard treatment was available.
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
Updated preliminary results in a subgroup analysis of 57 efficacy evaluable patients with HER2-positive metastatic breast cancer pre-treated with ado-trastuzumab emtansine showed that DS-8201 demonstrated a confirmed overall response rate of 61.4 percent and a disease control rate of 94.7 percent.
Daiichi Sankyo and Translational Sciences Conclude Agreement, After Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization
Daiichi Sankyo will return all rights to develop and commercialize Translational Sciences' investigational thrombus dissolving agent, TS23, after a successful Phase 1a clinical trial.
Daiichi Sankyo Initiates Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer
Daiichi Sankyo today announced the first patient has been enrolled in DESTINY-Gastric01, a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting ADC, in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma resistant or refractory to trastuzumab.
Data at SABCS and ASH Demonstrate Daiichi Sankyo Commitment to Advancing Science in Breast and Blood Cancer
Updated data from the ongoing phase 1 study of DS-8201, an investigational HER2-targeting ADC, in HER2-positive metastatic breast cancer as well as patients with HER2 low-expressing breast cancer will be highlighted as a Spotlight Poster Discussion at SABCS.
Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.
Berkeley Lights announced today a program with Daiichi Sankyo focused on using the Beacon platform to accelerate its cell line development workflow.
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
Daiichi Sankyo and Glycotope have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo's proprietary ADC tech with Glycotope's investigational tumor-associated TA-MUC1 antibody PankoMab-GEX.
Exelixis Provides Update On Collaborator Daiichi Sankyo, Inc.’s Phase III Clinical Progress With Esaxerenone (CS-3150), Including Positive Top-Line Results And Additional Pivotal Study
On a Roll: Kite Pharma Bags $250 Million CAR-T Deal From Daiichi Sankyo, Inc., Forms Joint Venture With Fosun Pharma
Daiichi Sankyo Cuts-and-Pastes for 5-Year Plan: Sister Companies Daiichi Sankyo, Inc. and Asubio Pharma Co., Ltd. Merge
Charleston Laboratories, Inc. And Daiichi Sankyo Announce Completion Of A Pharmacokinetics Study On CL-108